Please use this identifier to cite or link to this item:
|Title:||Increased breast cancer cell toxicity by palladination of the polyamine analogue N1,N11-bis(ethyl)norspermine||Authors:||Silva, Tânia M.
Fiuza, Sonia M.
Marques, M. Paula M.
|Keywords:||Breast cancer; Polyamine analogues; Palladium (Pd)(II) complexes; Platinum (Pt)(II) complexes; DNA damage; Cancer stem cells||Issue Date:||2014||Publisher:||Springer||Serial title, monograph or event:||Amino Acids||Volume:||46||Abstract:||Breast cancer is one of the most common malignant tumor forms among women and many women succumb to their disease. Thus, new anticancer agents that can efficiently improve patient survival are of the utmost importance. In this study, the effects of the polyamine analogues N1,N11-bis(ethyl)norspermine (BENSpm) and N1-cyclo-propylmethyl-N11-ethylnorspermine (CPENSpm) and the synthesized dinuclear complexes Pd2BENSpm (Pd- BENSpm), Pt2CPENSpm (Pt-CPENSpm) and Pd2Spm (Pd- Spm) were investigated in normal-like breast epithelial MCF-10A cells and the breast cancer cell lines JIMT-1 and L56BR-C1. The overall data show that palladination of BENSpm resulted in enhanced cytotoxicity, in contrast to platination of CPENSpm that reduced cytotoxicity, which might be explained by differences in the cellular uptake of Pd-BENSpm and Pt-CPENSpm. BENSpm and Pd-BENSpm treatment reduced the CD44?CD24- putative cancer stem cell population, evaluated by flow cytometry. Furthermore, Pd-BENSpm was the most efficient compound regarding induction of DNA damage and decrease in colony formation in soft agar. Pt-CPENSpm and Pd-Spm, on the other hand, were shown to be the least toxic compounds of all tested. Pd-Spm efficiently reduced the cellular glutathione levels, which probably was a consequence of its metabolic inactivation by conjugation to this endogenous thiol. The normal-like cells were found to be less sensitive to the agents than the breast cancer cells. Our findings show that Pd-BENSpm exhibits promising anticancer effects which render it suitable for further optimization to develop a new metal-based chemotherapeutic drug for breast cancer treatment.||URI:||http://hdl.handle.net/10316/25473||DOI:||10.1007/s00726-013-1621-y||Rights:||openAccess|
|Appears in Collections:||FCTUC Ciências da Vida - Artigos em Revistas Internacionais|
Show full item record
Files in This Item:
|art%3A10.1007%2Fs00726-013-1621-y.pdf||585.86 kB||Adobe PDF||View/Open|
checked on Feb 18, 2020
WEB OF SCIENCETM
checked on May 29, 2020
checked on Aug 6, 2020
checked on Aug 6, 2020
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.